Research Methodology Followed for This Study:
Top-down and bottom-up approaches were used to validate the size of the global cell viability assays market and estimate the size of other dependent submarkets. Various secondary sources such as directories; industry journals; databases such as D&B Hoovers, Bloomberg Business, and Factiva; and annual reports of companies have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both the supply and demand sides have been interviewed to obtain and validate information as well as to assess the dynamics of this market.
Global Industry Segmentation:
By product, the consumables segment is expected to account for the largest share of the cell viability assays market in 2018
On the basis of product, the consumables segment is expected to account for the largest share of the cell viability assays market in 2018. This large share can be attributed to the repeated consumption of consumables in various cell viability procedures. The growing focus on stem cell and cancer research is another major driver for the growth of the cell viability consumables market along with the growing application of cell viability in quality control procedures in various industries, such as food and beverage, pharmaceutical, biotechnology products manufacturing, environmental monitoring, and water treatment.
Download PDF Brochure@
By application, the drug discovery & development application segment is estimated to hold the largest share in 2018
Based on application, the cell viability assays market is segmented into drug discovery & development, basic research, stem cell research, clinical & diagnostic applications, and other applications. In 2018, the drug discovery & development application segment is expected to account for the largest share of the global cell viability assays market. The large share of this segment can be attributed to the rising incidence and prevalence of chronic and infectious diseases and increasing government support for developing new treatments for various human diseases.
# Manufacturers of cell viability instruments and consumables
# Distributors of cell viability instruments and consumables
# Research and development organizations
# Hospitals and clinics
# Diagnostic centers
# Market research and consulting firms
# Venture capitalists and investors
By end user, the pharmaceutical and biotechnology companies segment is estimated to hold the largest share of the cell viability assays market in 2018
On the basis of end user, the cell viability assays market is segmented into pharmaceutical and biotechnology companies, hospital and diagnostic laboratories, academic and research institutes, and other end users (food and beverage companies and environmental testing companies). The pharmaceutical and biotechnology companies segment is expected to account for the largest share in 2018. The large share of this segment can be attributed to the increasing number of R&D activities undertaken by these companies for the development of biopharmaceutical products.
Geographical Growth Dynamics:
North America to dominate the market in 2018
North America is expected to account for the largest share of the cell viability assays market in 2018, followed by Europe and Asia Pacific. The growing incidence rate of various infectious diseases, investment initiatives by the government, and the high-quality infrastructure for clinical and laboratory research are the major factors responsible for the large share of the North American cell viability assays market. Moreover, a number of major global players are based in the US, owing to which, the US is a center for innovation in the cell viability assays market.
Request Sample Pages@
The prominent players in the cell viability assays market are Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), GE Healthcare (US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), G-Biosciences (US), Creative Bioarray (US), Danaher Corporation (US), and Becton, Dickinson and Company (US).
Major leaders are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies of product launches, expansions, agreements, collaborations, and acquisitions.